Cargando…

Psoriasis and Liver Damage in HIV-Infected Patients

Background/objectives: Psoriasis is the most frequent skin disease in HIV-infected patients. Nonalcohol fatty liver disease (NAFLD) is more prevalent in patients with psoriasis. We report the prevalence of psoriasis and NAFLD and investigate risk factors of liver damage in HIV-infected patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Busca Arenzana, Carmen, Quintana Castanedo, Lucía, Chiloeches Fernández, Clara, Nieto Rodríguez, Daniel, Herranz Pinto, Pedro, Delgado Hierro, Ana Belén, Olveira Martín, Antonio, Montes Ramírez, María Luisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147812/
https://www.ncbi.nlm.nih.gov/pubmed/34064387
http://dx.doi.org/10.3390/cells10051099
_version_ 1783697710473281536
author Busca Arenzana, Carmen
Quintana Castanedo, Lucía
Chiloeches Fernández, Clara
Nieto Rodríguez, Daniel
Herranz Pinto, Pedro
Delgado Hierro, Ana Belén
Olveira Martín, Antonio
Montes Ramírez, María Luisa
author_facet Busca Arenzana, Carmen
Quintana Castanedo, Lucía
Chiloeches Fernández, Clara
Nieto Rodríguez, Daniel
Herranz Pinto, Pedro
Delgado Hierro, Ana Belén
Olveira Martín, Antonio
Montes Ramírez, María Luisa
author_sort Busca Arenzana, Carmen
collection PubMed
description Background/objectives: Psoriasis is the most frequent skin disease in HIV-infected patients. Nonalcohol fatty liver disease (NAFLD) is more prevalent in patients with psoriasis. We report the prevalence of psoriasis and NAFLD and investigate risk factors of liver damage in HIV-infected patients with psoriasis. Methods: We performed a retrospective observational study. Steatosis was defined as indicative abdominal ultrasound findings, CAP (controlled attenuated parameter by transient elastography) > 238 dB/m, and/or triglyceride and glucose index (TyG) > 8.38. Significant (fibrosis ≥ 2) and advanced liver fibrosis (fibrosis ≤ F3) were studied by transient elastography (TE) and/or FIB-4 using standard cutoff points. FIB-4 (Fibrosis 4 score) results were adjusted for hepatitis C (HCV)-coinfected patients. Results: We identified 80 patients with psoriasis (prevalence, 1.5%; 95% CI, 1.1–1.8). Psoriasis was severe (PASI > 10 and/or psoriatic arthritis) in 27.5% of cases. The prevalence of steatosis was 72.5% (95% CI, 65–85). Severe psoriasis was an independent risk factor for steatosis (OR, 12; 95% CI, 1.2–120; p = 0.03). Significant liver fibrosis (p < 0.05) was associated with HCV coinfection (OR 3.4; 95% CI, 1.1–10.6), total CD4 (OR 0.99; 95% CI, 0.99–1), and time of efavirenz exposure (OR 1.2; 95% CI, 1.0–1.3). Conclusions: The prevalence of psoriasis in HIV-infected patients was similar to that of the general population. Steatosis is highly prevalent, and severe psoriasis is an independent risk factor for steatosis in HIV-infected patients.
format Online
Article
Text
id pubmed-8147812
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81478122021-05-26 Psoriasis and Liver Damage in HIV-Infected Patients Busca Arenzana, Carmen Quintana Castanedo, Lucía Chiloeches Fernández, Clara Nieto Rodríguez, Daniel Herranz Pinto, Pedro Delgado Hierro, Ana Belén Olveira Martín, Antonio Montes Ramírez, María Luisa Cells Communication Background/objectives: Psoriasis is the most frequent skin disease in HIV-infected patients. Nonalcohol fatty liver disease (NAFLD) is more prevalent in patients with psoriasis. We report the prevalence of psoriasis and NAFLD and investigate risk factors of liver damage in HIV-infected patients with psoriasis. Methods: We performed a retrospective observational study. Steatosis was defined as indicative abdominal ultrasound findings, CAP (controlled attenuated parameter by transient elastography) > 238 dB/m, and/or triglyceride and glucose index (TyG) > 8.38. Significant (fibrosis ≥ 2) and advanced liver fibrosis (fibrosis ≤ F3) were studied by transient elastography (TE) and/or FIB-4 using standard cutoff points. FIB-4 (Fibrosis 4 score) results were adjusted for hepatitis C (HCV)-coinfected patients. Results: We identified 80 patients with psoriasis (prevalence, 1.5%; 95% CI, 1.1–1.8). Psoriasis was severe (PASI > 10 and/or psoriatic arthritis) in 27.5% of cases. The prevalence of steatosis was 72.5% (95% CI, 65–85). Severe psoriasis was an independent risk factor for steatosis (OR, 12; 95% CI, 1.2–120; p = 0.03). Significant liver fibrosis (p < 0.05) was associated with HCV coinfection (OR 3.4; 95% CI, 1.1–10.6), total CD4 (OR 0.99; 95% CI, 0.99–1), and time of efavirenz exposure (OR 1.2; 95% CI, 1.0–1.3). Conclusions: The prevalence of psoriasis in HIV-infected patients was similar to that of the general population. Steatosis is highly prevalent, and severe psoriasis is an independent risk factor for steatosis in HIV-infected patients. MDPI 2021-05-04 /pmc/articles/PMC8147812/ /pubmed/34064387 http://dx.doi.org/10.3390/cells10051099 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Busca Arenzana, Carmen
Quintana Castanedo, Lucía
Chiloeches Fernández, Clara
Nieto Rodríguez, Daniel
Herranz Pinto, Pedro
Delgado Hierro, Ana Belén
Olveira Martín, Antonio
Montes Ramírez, María Luisa
Psoriasis and Liver Damage in HIV-Infected Patients
title Psoriasis and Liver Damage in HIV-Infected Patients
title_full Psoriasis and Liver Damage in HIV-Infected Patients
title_fullStr Psoriasis and Liver Damage in HIV-Infected Patients
title_full_unstemmed Psoriasis and Liver Damage in HIV-Infected Patients
title_short Psoriasis and Liver Damage in HIV-Infected Patients
title_sort psoriasis and liver damage in hiv-infected patients
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8147812/
https://www.ncbi.nlm.nih.gov/pubmed/34064387
http://dx.doi.org/10.3390/cells10051099
work_keys_str_mv AT buscaarenzanacarmen psoriasisandliverdamageinhivinfectedpatients
AT quintanacastanedolucia psoriasisandliverdamageinhivinfectedpatients
AT chiloechesfernandezclara psoriasisandliverdamageinhivinfectedpatients
AT nietorodriguezdaniel psoriasisandliverdamageinhivinfectedpatients
AT herranzpintopedro psoriasisandliverdamageinhivinfectedpatients
AT delgadohierroanabelen psoriasisandliverdamageinhivinfectedpatients
AT olveiramartinantonio psoriasisandliverdamageinhivinfectedpatients
AT montesramirezmarialuisa psoriasisandliverdamageinhivinfectedpatients